Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refract...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Biol Ther
Glavni autori: Samulitis, Betty K, Pond, Kelvin W, Pond, Erika, Cress, Anne E, Patel, Hitendra, Wisner, Lee, Patel, Charmi, Dorr, Robert T, Landowski, Terry H
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2014
Teme:
Research Papers
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623403/
https://ncbi.nlm.nih.gov/pubmed/25485960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.986967
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items